Cargando…

Use of Drugs for Off-Label Indications: Living in the Same World

Detalles Bibliográficos
Autor principal:	Barbuto, John P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2003
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437251/ https://www.ncbi.nlm.nih.gov/pubmed/14664666 http://dx.doi.org/10.18553/jmcp.2003.9.6.570

Ejemplares similares

Off-label use of drugs: An evil or a necessity?
por: Gota, Vikram, et al.
Publicado: (2015)

Off-label indications for bioresorbable scaffolds: “Beethoven can, but you cannot”
por: Gutiérrez-Chico, Juan Luis, et al.
Publicado: (2016)

When is off-label off-road?
por: de Vries, E G E, et al.
Publicado: (2019)

Challenges on off label medicine use
por: Carvalho, Marisa Lima
Publicado: (2016)

A tale of two drugs: Off and on-label
por: Narayanan, Raja, et al.
Publicado: (2017)

Evaluating the Use of Dalbavancin for Off-Label Indications
por: Taylor, Katherine, et al.
Publicado: (2022)

Gabapentin May Be Appropriate for Off-Label Uses
por: Davis, Shawn
Publicado: (2003)

Regulatory Actions on the Off-Label Use of Prescription Drugs: Ongoing Controversy and Contradiction in 2009 and 2010
por: Fairman, Kathleen A., et al.
Publicado: (2010)

614. Evaluating the Use of Dalbavancin for Off-Label Indications
por: Taylor, Katherine, et al.
Publicado: (2021)

Off-label, but on target: the evidence needed to implement alternative dosing regimens of anticancer drugs
por: Overbeek, J.K., et al.
Publicado: (2023)

Contradictory Actions on Off-Label Use of Prescription Drugs? The FDA and CMS Versus the U.S. Justice Department
por: Curtiss, Frederic R.
Publicado: (2009)

Off-label Medication Use: A Double-edged Sword
por: Agarwal, Vandana
Publicado: (2021)

Biologics in Dermatology: Off-Label Indications
por: Mitra, Debdeep, et al.
Publicado: (2020)

Assessment of novel technologies in healthcare - off-label use of drugs and the ethics of implementation and distribution of COVID-19 vaccines
por: Avelino-Silva, Vivian Iida, et al.
Publicado: (2021)

Off-Label Use vs Off-Label Marketing of Drugs: Part 1: Off-Label Use—Patient Harms and Prescriber Responsibilities
por: Van Norman, Gail A.
Publicado: (2023)

Pulmonary Artery Stents-Still "Off Label"
por: Kim, Seong-Ho
Publicado: (2012)

Less explored off-label indications of dexmedetomidine
por: Nair, Abhijit
Publicado: (2017)

A brief note on randomized controlled trials and compassionate/off-label use of drugs in the early phases of the COVID-19 pandemic
por: Bassetti, Matteo, et al.
Publicado: (2020)

Automated Detection of Off-Label Drug Use
por: Jung, Kenneth, et al.
Publicado: (2014)

Off-label drugs for obesity
por: Morgan, Andy, et al.
Publicado: (2022)

Off-Label and Off-NCCN Guidelines Uses of Antineoplastic Drugs in China
por: WANG, Weilan, et al.
Publicado: (2013)

Off-label use of medicines: Medical research and medical practice
por: Khamar, Bakulesh
Publicado: (2007)

Multiple drugs: Various toxicities, off-label use and no response to off-label therapy: case report
Publicado: (2021)

Pharmacotherapy of Schizophrenic Patients: Preponderance of Off-Label Drug Use
por: Pickar, David, et al.
Publicado: (2008)

Daratumumab: new indications revolving around "off-targets"
por: Ofran, Yishai
Publicado: (2021)

Off-label drugs use in pediatric palliative care
por: De Zen, Lucia, et al.
Publicado: (2018)

Recommendations on Off-Label Drug Use in Pediatric Guidelines
por: Meng, Min, et al.
Publicado: (2022)

Off-Label Antipsychotic Prescribing for Persons With Dementia in Assisted Living
por: Wretman, Christopher, et al.
Publicado: (2020)

New global surgical and anaesthesia indicators in the World Development Indicators dataset
por: Raykar, Nakul P, et al.
Publicado: (2017)

Out of Illness, Into Life: Pain Management and the Need for Triptans
por: Barbuto, John P.
Publicado: (2003)

Off-label drugs for weight management
por: Hendricks, Ed J
Publicado: (2017)

Emerging and Re-Emerging Diseases: Novel Challenges in Today’s World or More of the Same?
por: Mesquita, João R.
Publicado: (2021)

Bipolar Disorder Pills in Perspective: Questions From Peer Review
por: Barbuto, John P.
Publicado: (2005)

Treatment of recurrent respiratory papillomatosis and adverse reactions following off-label use of cidofovir (Vistide(®))
por: Tjon Pian Gi, Robin E. A., et al.
Publicado: (2011)

Multiple drugs: Drugs ineffective and off-label use: case report
Publicado: (2022)

Beyond Narcotics for Effective Pain Management
por: Barbuto, John
Publicado: (2003)

ADHD: Disease or Social Misfit?
por: Barbuto, John
Publicado: (2005)

Addressing the “What do we have to lose? Just give the drug” rationale: making the case for clinical trials and against off-label use in COVID-19
por: Ramnath, Venktesh R., et al.
Publicado: (2020)

Off-label indications for atypical antipsychotics: A systematic review
por: Fountoulakis, Konstantinos N, et al.
Publicado: (2004)

Regulating off-label drug use in India: The arena for concern
por: Oberoi, Sukhvinder Singh
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_m9cnd1p1lpmcij3cnsc5cir4rm